{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"40"}],"units":"Participants"}],"description":"Lack of donor-derived neutrophil engraftment. The frequency of subjects experiencing primary graft failure by 56 days will be described.","groups":[{"description":"Participants received one of three regimens: cyclophosphamide and total body irradiation; busulfan and cyclophosphamide; or fludarabine and busulfan","id":"OG000","title":"Myeloablative Conditioning (MAC)"},{"description":"Participants received one of two regimens: fludarabine, cyclophosphamide, and low-dose total body irradiation","id":"OG001","title":"Reduced Intensity Conditioning (RIC)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Primary graft failure Lack of donor-derived neutrophil engraftment. The frequency of subjects experiencing primary graft failure by 56 days will be described. Transplanted participants surviving a minimum of 14 days post HCT and have complete data for both event status and event date.","reportingStatus":"POSTED","timeFrame":"56 days post-transplant","title":"Cumulative Incidence of Primary Graft Failure","type":"SECONDARY","unitOfMeasure":"Participants"}